Œ¤‹†¬‰Ê

1) Horiuchi T, Mitoma H, Tsukamoto H, Harashima S, Shimoda T: Transmembrane TNF-a. Structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) in press

2) Nishimoto K,et al. Horiuchi T (25l’†17”Ô–Ú): Association study of TRAF1-C5 polymorphisms with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in Japanese.
Ann. Rheum. Dis. 2009 Mar 30. [Epub ahead of print]

3) Kiyohara C, Washio M, Horiuchi T, Tada Y, Asami T, Ide S, Atsumi T, Kobashi G, Takahashi H, and the Kyushu Sapporo SLE (KYSS) Study Group : Cigarette smoking, STAT4 and TNFRSF1B polymorphisms, and systemic lupus erythematosus in a Japanese population.J. Rheumatol. 36(10): 2195-2203, 2009

4) Horiuchi T, Washio M, Kiyohara C, Tsukamoto H, Tada Y, Asami T,Ide S, Kobashi G, Takahashi@H, and the Kyushu Sapporo SLE (KYSS) Study Group : Combination of TNF-RII, CYP1A1 and GSTM1 polymorphisms and the risk of Japanese SLE: findings from the KYSS study.
Rheumatology (Oxford) 48: 1045-1049, 2009

5) Kiyohara C, Washio M, Horiuchi T, Tada Y, Asami T,Ide S, Takahashi H, Kobashi G, and the Kyushu Sapporo SLE (KYSS) Study Group: Cigarette smoking, N-acetyltransferase 2 polymorphisms and systemic lupus erythematosus in a Japanese population. Lupus 18(7): 630-638, 2009

6) Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, To K, Harashima S, Hatta N, Harada M : Mechanisms for cytotoxic effects of anti-TNF agents on transmembrane TNF-expressing cells: comparison among infliximab, etanercept and adalimumab.
Arthritis Rheum. 58(5): 1248-1257, 2008

7) Kobayashi S,et al.Horiuchi T (25l’†14”Ô–Ú): Association of STAT4 with susceptibility to rheumatoid arthritis and systemic lupus erythematosus in Japanese. Arthritis Rheum. 58(7): 1940-1946, 2008

8) Tamimoto Y, Horiuchi T, Tsukamoto H, Otsuka J, Mitoma H, Kimoto Y, Nakashima H, Muta K, Abe Y, Kiyohara C, Ueda A, Nagasawa K, Yoshizawa S, Shimoda T, Harada M: A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans’ syndrome: Immunological analysis of B cells, T cells and cytokines.Rheumatology (Oxford) 47: 821-827, 2008

9) Miyagawa H, Yamai M, Sakaguchi D, Kiyohara C, Tsukamoto H, Kimoto Y, Nakamura T, Lee J-H, Tsai C-Y, Chiang B-L, Shimoda T, Harada M, Tahira T, Hayashi K, Horiuchi T :@Association of polymorphisms in complement component C3 gene with susceptibility to systemic
lupus erythematosus.Rheumatology (Oxford) 47: 158-164, 2008

10) Kikuchi Y, Koarada S, Nakamura S, Yonemitsu N, Tada Y, Haruta Y, Morito F, Ohta A, Miyake K, Horiuchi T, Nagasawa K: Increase of RP105-lacking activated B cells in the peripheral blood and salivary glands in patients with Sjogren’s syndrome. Clin. Exp. Rheumatol. 26(1): 5-12, 2008

11) Horiuchi T, Kiyohara C, Tsukamoto H, Sawabe T, Furugo I, Yoshizawa S, Ueda A, Nakamura T, Tada Y, Kimoto Y, Mitoma H, Harashima SI, Yoshizawa S, Shimoda T, Okamura S, Nagasawa K, Harada M.: A functional M196R polymorphism of tumor necrosis factor receptor type 2 is associated with systemic lupus erythematosus: A case-control study and a meta-analysis. Ann. Rheum. Dis. 66(3): 320-324, 2007

12) Tao K, Fujii M, Tsukumo SI, Maekawa Y, Kishihara K, Kimoto Y, Horiuchi T, Hisaeda H, Akira S, Kagami S, Yasutomo K : Genetic variations of Toll like receptor 9 predispose to systemic lupus erythematosus in Japanese population. Ann. Rheum. Dis. 66(7): 905-909, 2007

Îƒ–’Ø—Ç–¾iŒ¤‹†•ª’SŽÒj

1) Kirino Y, Takeno M, Watanabe R, Murakami S, Kobayashi M, Ideguchi H, Ihata A, Ohno S, Ueda A, Mizuki N, Ishigatsubo Y: Association of reduced heme oxygenase-1 with excessive Toll-like receptor 4 expression in peripheral blood mononuclear cells in Behcet’s disease. Arthritis Res Ther. 10(1):R16, 2008.

2) Kirino Y, Takeno M, Murakami S, Kobayashi M, Miura K, Ideguchi H, Ohno S, Ueda A, Ishigatsubo Y : Tumor necrosis factor a acceleration of inflammatory responses by down-regulating heme oxygenase 1 in human peripheral monocytes. Arthritis Rheum. 56(2): 464-475, 2007.

•ˆäCŽ¡iŒ¤‹†•ª’SŽÒj

1) Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomita M, Nishimoto N, Kishimoto T: Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371(9617):998-1006, 2008
 
˜h”ö¹ˆêiŒ¤‹†•ª’SŽÒj

1) Washio M, Mori M, Khan MMH, Sakaguchi F, Watanabe Y, Ozawa K, Hayashi K, the JACC study group. Diabetes mellitus and kidney cancer risk.The results of Japan collaborative cohort study for evaluation of cancer risk (JACC study). Int. J. Urology 14: 393-397, 2007
 
–ª“c´ŽŸiŒ¤‹†•ª’SŽÒj

1) Nagashima T, et al. Minota Si11l’†11”ԖځjFIncrease in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis. J.Rheumatol. 35(5):936-938, 2008

 “팴_ˆêiŒ¤‹†•ª’SŽÒj

1) Kusuhara K, Ohga S, Hoshina T, Saito M, Sasaki Y, Fujita M, Hara T : Disseminated BCG lymphadenitis in a patient with gp91phox- chronic granulomatous disease 25 years after vaccination. Eur. J. Pediatr .168: 745-747, 2009.

 ‚‹´—TŽ÷iŒ¤‹†•ª’SŽÒj

1) Yamamoto M, Takahashi H, Hasebe K, Suzuki C, Naishiro Y, Hayashi T, Ishida T, Shinomura Y: The analysis of interleukin-6 in patients with systemic IgG4-related plasmacytic syndrome-expansion of SIPS to the territory of Castleman’s disease. Rheumatology (Oxford) 48: 860-862,2009
 
“¡ˆä—²•viŒ¤‹†•ª’SŽÒj

1) Ito Y, et al. Fujii Ti18l’†17”ԖځjFgd T cells are the predominant source of IL-17 in the affected joints of collagen-induced arthritis, but not in rheumatoid arthritis. Arthritis Rheum. 60: 2294-2303, 2009

  • ƒƒjƒ…[
  • ƒƒbƒZ[ƒW
  • Œ¤‹†‘gD
  • Œ¤‹†ŠT—v
  • Œ¤‹†Œv‰æ
  • Œ¤‹†¬‰Ê
  • ƒjƒ…[ƒX
  • ƒŠƒ“ƒN
  • ƒTƒCƒgƒ}ƒbƒv
  • ƒz[ƒ€